Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 06

2123P - Value of immuno-nutritional scores in the prognosis of hospitalised patients with lung cancer

Date

21 Oct 2023

Session

Poster session 06

Topics

Supportive Care and Symptom Management

Tumour Site

Small Cell Lung Cancer;  Non-Small Cell Lung Cancer

Presenters

Jesús López

Citation

Annals of Oncology (2023) 34 (suppl_2): S1080-S1134. 10.1016/S0923-7534(23)01268-1

Authors

J.P. López1, D. Jiménez Bou1, I. Ruiz-Gutiérrez1, L. Gutierrez Sainz1, C. Navas-Jiménez1, J.I. Alonso-Eiras1, Á. García-Zamarriego1, D. Sanchez Cabrero1, L. Ruiz Jimenez Ubeda1, A. Pertejo1, J.P. Perez Wert1, A. Alonso-Babarro2, P. Cruz Castellanos1, O. Higuera Gomez1, J. de Castro Carpeño1

Author affiliations

  • 1 Medical Oncology Department, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 2 Palliative Care Unit, Hospital Universitario La Paz, 28046 - Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2123P

Background

Immuno-nutritional scores like neutrophil-lymphocyte ratio (NLR), prognostic nutritional index (PNI), modified Glasgow prognostic score (mGPS) and controlling nutritional status (CONUT) have been developed to reflect the chronic inflammatory state and malnutrition induced by cancer, and to predict clinical outcomes. This study aims to investigate the prognostic value of these scores in hospitalized patients with lung cancer as we know that unscheduled admission in patients with cancer may imply organ fragility.

Methods

In this retrospective study, we examined patients with lung cancer and unscheduled hospitalizations that took place between June 2021 and May 2022 within the Medical Oncology Service of La Paz University Hospital in Madrid, Spain.

The optimal cutoff for continuous variables was evaluated with Youden index. Survival since admission was estimated with the Kaplan-Meier method. Univariate and multivariate analyses were performed by Cox regression model to determine independent prognostic factors. Areas under the curve (AUCs) or ROCs were calculated to evaluate the discriminatory ability.

Results

We admitted 158 patients with a median age of 68 years, majority of male (66.5%) and stage IV predominance (84.8%). The median follow-up was 14.9 months. The median overall survival since admission was 3.3 months (95%CI: 1.86-7.74). The optimal cut-off value for NLR was calculated to be 6 (Youden index=0.2) and for PNI was 40 (Youden index=0.1). In univariate analysis, poorer survival was associated with NLR>6 (1.87 vs 7.40 months, p=0.006, HR 1.67, 95%CI 1.16-2.42) and PNI<40 (1.67 vs 4.97 months, p=0.044, HR 1.49, 95%CI 1.01-2.20) and was not associated with CONUT (p=0.70) or mGPS (p=0.067). In the multivariate analysis only NLR>6 was an independent prognostic factor (p=0.042, HR 1.61, 95%CI 1.02-2.57). The ROC curve to evaluate the discriminatory ability of 30-day mortality was only significant in the case of NLR>6 (p=0.035, AUC 0.599, 95%CI 0.51-0.69).

Conclusions

In our setting, NLR was the most robust score for estimating prognosis in hospitalized patients with lung cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.